Quanterix IPO

12/7/2017

IPO

$64,500,000

We currently expect to use the net proceeds from this offering: (1) to expand our life sciences commercial operations to grow and support the installed base of our products among life sciences research customers in the United States and internationally; (2) to improve and update our Simoa technology and instruments and to develop additional assays, including assays for nucleic acid detection; (3) to support the launch of our new Quanterix SR-X instrument, currently scheduled for launch in 2018; (4) to potentially move into a larger corporate headquarters in order to have the appropriate infrastructure to support the increase in our employee base in addition to an increase in our manufacturing footprint; (5) to pursue regulatory approvals or clearances to develop instruments, assay kits and consumables in areas outside of life science research, including potentially LDTs, IVD tests and other markets, and, subject to receipt of such necessary regulatory approvals or clearances, to develo

Publicly-held

Medical Devices & Instruments

113 Hartwell Ave.
Lexington, MA 02421
USA

At Quanterix (NASDAQ: QTRX), our principal focus is to improve human health by providing physicians, drug developers, and researchers with the ability to detect and analyze important biomolecules within complex biological samples at the level of single molecules.